公开(公告)号：US20170165337A1

公开(公告)日：2017-06-15

申请号：US15374054

申请日：2016-12-09

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/725 ,  C12N15/115 ,  C07K7/06 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/34 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170080070A1

公开(公告)日：2017-03-23

申请号：US15357757

申请日：2016-11-21

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sara KUTSCHER

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  C07K14/725 ,  C07K14/435 ,  C07K14/74

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C07K2317/70 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20170037107A1

公开(公告)日：2017-02-09

申请号：US15199244

申请日：2016-06-30

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/705 ,  A61K39/00 ,  C12N5/0783 ,  C07K16/28 ,  C07K16/30 ,  C07K14/74 ,  C07K14/725 ,  C12N15/115

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4705 ,  C07K14/4738 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/30 ,  C12N2501/50 ,  C12N2501/998 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/56977 ,  G01N33/57449 ,  G01N33/57492 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170037093A1

公开(公告)日：2017-02-09

申请号：US15199338

申请日：2016-06-30

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  A61K39/00 ,  C07K14/74 ,  C07K14/725

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20160289296A1

公开(公告)日：2016-10-06

申请号：US15082920

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Colette SONG

IPC: C07K14/74 ,  C12N5/0783 ,  C07K16/28 ,  G06F19/20 ,  A61K39/00 ,  C07K16/30

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3038 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/33 ,  C07K2319/55 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230265158A1

公开(公告)日：2023-08-24

申请号：US18054566

申请日：2022-11-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C12N9/64 ,  G01N33/566 ,  C12N5/0783 ,  C07K14/47 ,  G01N33/569 ,  C12Q1/6886 ,  A61K45/06 ,  A61K39/00 ,  A01N37/46 ,  A61K38/17 ,  C07K16/28 ,  A61K38/06 ,  C07K14/00 ,  C07K16/30 ,  A61K38/08 ,  C07K16/18 ,  G01N33/50 ,  C07K7/02 ,  C07K7/06 ,  C07K14/725 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/30 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/566 ,  G01N33/5088 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/7051 ,  G01N2333/70503 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230235016A1

公开(公告)日：2023-07-27

申请号：US18052824

申请日：2022-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  G01N33/569 ,  A61K38/17 ,  C12Q1/6886 ,  A01N37/46

CPC classification number: C07K14/70539 ,  A61K38/06 ,  C12N9/6491 ,  C12N5/0636 ,  C07K16/30 ,  C07K14/4748 ,  A61K39/0011 ,  C07K16/2833 ,  A61K45/06 ,  C07K14/001 ,  C07K7/06 ,  C07K7/02 ,  G01N33/505 ,  G01N33/566 ,  G01N33/5088 ,  A61K39/0005 ,  C07K16/18 ,  C07K14/47 ,  C12N5/0638 ,  A61K38/08 ,  C07K14/7051 ,  G01N33/56972 ,  C07K14/4702 ,  A61K38/1774 ,  C12Q1/6886 ,  G01N33/56977 ,  A01N37/46 ,  C07K2317/34 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/7051 ,  A61K2039/54 ,  G01N2333/70539 ,  C07K2317/31 ,  C07K2317/24 ,  G01N2333/70503 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2502/11 ,  A61K2039/572 ,  G01N2333/47 ,  C12N2501/998 ,  C12Y304/24 ,  A61K2039/57 ,  A61K2039/585 ,  A61K38/00

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230226161A1

公开(公告)日：2023-07-20

申请号：US18158606

申请日：2023-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  A61P35/00 ,  C12Q1/6886 ,  C12N15/115 ,  C07K16/28 ,  C07K14/74 ,  C07K16/30 ,  G01N33/574 ,  C07K7/08 ,  C07K14/725 ,  C12N5/0783 ,  C07K7/06 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C12Q1/6886 ,  C12N15/115 ,  C07K16/2833 ,  C07K14/70539 ,  C07K16/3076 ,  G01N33/57492 ,  C07K7/08 ,  C07K14/7051 ,  C12N5/0636 ,  C07K7/06 ,  C07K14/4748 ,  C12Q2600/106 ,  G01N2333/70539 ,  A61K39/00 ,  A61K2039/5158 ,  C12N2310/16 ,  C12Q2600/156 ,  C12N2501/50 ,  C07K2319/40

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230212244A1

公开(公告)日：2023-07-06

申请号：US18063418

申请日：2022-12-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Oliver SCHOOR ,  Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/113 ,  C07K14/725 ,  C07K16/30

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K39/001154 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3046 ,  C07K16/3076 ,  C12N5/0636 ,  C12N15/1138 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K2317/34 ,  C12N2310/16 ,  C12N2501/50

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230201321A1

公开(公告)日：2023-06-29

申请号：US17820432

申请日：2022-08-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Andrea MAHR

IPC: A61K39/00 ,  G16B25/00 ,  C07K14/64 ,  C07K14/705 ,  C07K16/00 ,  G16B25/10 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

CPC classification number: A61K39/0011 ,  G16B25/00 ,  C07K14/64 ,  C07K14/70503 ,  C07K16/00 ,  G16B25/10 ,  C07K14/4743 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2809 ,  C12N5/0638 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/57484 ,  G01N33/6872 ,  A61K2039/80 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/40 ,  C12N2310/16 ,  C12Q2600/136 ,  G01N2333/70539

Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.